HC Wainwright Analysts Boost Earnings Estimates for Precigen

Precigen, Inc. (NASDAQ:PGEN) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Precigen in a report issued on Thursday, March 26th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of ($0.03) per share for the quarter, up from their previous estimate of ($0.05). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.02) EPS.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The company had revenue of $4.57 million for the quarter, compared to the consensus estimate of $8.29 million.

A number of other research firms have also weighed in on PGEN. Wall Street Zen raised shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Citizens Jmp lifted their price objective on Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 26th. Finally, Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.50.

Precigen Price Performance

NASDAQ PGEN opened at $3.87 on Monday. Precigen has a 1 year low of $1.11 and a 1 year high of $5.47. The company has a fifty day simple moving average of $4.05 and a 200 day simple moving average of $3.97. The company has a current ratio of 3.09, a quick ratio of 2.83 and a debt-to-equity ratio of 4.46. The company has a market cap of $1.37 billion, a P/E ratio of -2.89 and a beta of 1.10.

Hedge Funds Weigh In On Precigen

Large investors have recently bought and sold shares of the stock. Investment Insight Wealth Management LLC acquired a new stake in Precigen in the 4th quarter worth $443,000. Invesco Ltd. increased its holdings in shares of Precigen by 250.8% during the 4th quarter. Invesco Ltd. now owns 373,782 shares of the biotechnology company’s stock worth $1,562,000 after purchasing an additional 267,223 shares during the period. NewEdge Advisors LLC acquired a new position in shares of Precigen during the fourth quarter valued at about $45,000. XTX Topco Ltd lifted its stake in shares of Precigen by 25.2% in the fourth quarter. XTX Topco Ltd now owns 49,668 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 10,005 shares during the period. Finally, VARCOV Co. bought a new stake in shares of Precigen in the fourth quarter valued at about $224,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.